THE ROADMAP SERIES

 

The HIV Drug Pipeline and its Patents: August 2013
[Download here]

In August 2013, the Initiative for Medicines, Access & Knowledge (I-MAK) created The Roadmap: The HIV Drug Pipeline and its Patents, the first report to showcase clinical, cost, and legal/patent information on important HIV antiretroviral (ARV) medicines in the pipeline. It aimed to help expand access to the next generation of life-saving ARVs in multiple ways. Using The Roadmap, advocates can decide which medicines need short- or long-term attention and make informed decisions about the best strategies to pursue, such as patent oppositions, compulsory licenses (CL), voluntary license (VL) negotiations, and/or direct advocacy.

 

The Roadmap Special Edition Report on Dolutegravir: June 2017
[Download Here]

In order to provide key information updates for prioritized ARVs, I-MAK created The Roadmap Special Edition Report on Dolutegravir (DTG). This report expands on the information provided in the original Roadmap to equip stakeholders with current clinical, cost, and patent information to inform decision-making about the best strategies to expand currently limited access to DTG, a second-generation, best in class HIV integrase strand transfer inhibitor that greatly improves upon drugs in its class and is highly suitable for large treatment programs in low- and middle-income countries. 

 

Why did we create the Roadmap series?

The Roadmap provides the opportunity to be proactive and create a positive agenda in anticipation of medicines that will be relevant for low- and middle-income countries. Without an analysis of pipeline products, the global treatment community is left in a position of being reactive to the behavior of originator companies. In addition, many assume that all pipeline drugs are new and innovative compounds. This research helps assess the level of actual innovation (and therefore patentability) of each product, thereby creating an accurate and comprehensive understanding of the HIV drug pipeline. Assessments of efficacy and inventive step contained herein are based on currently known interpretations of patent law.

Note: If you are using the April 2013 Edition, please make note of the Aug 2013 update attached here [download]